The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Review article: metoclopramide and tardive dyskinesia
Open accessAbstract
Summary: Background Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long‐term or high‐dose use of this medication because of the risk of developing tardive dyskinesia. Aims To review the mechanism of action and pharmacokinetic properties of metoclopramide, the risk of metoclopramide‐induced tardive dyskinesia, potential mechanisms that may alter and to summarize the clinical context for appropriate use of the drug. Methods We conducted a PubMed search using the following key words and combined searches: metoclopramide, neuroleptics, tardive dyskinesia, incidence, prevalence, dopamine, receptors, pharmacokinetic, pharmacology, pharmacogenetics, DRD3 Ser9Gly polymorphism, cytochrome P450, p‐glycoprotein, risk factors, gastroparesis, outcome, natural history. Results Available data show that risk of tardive dyskinesia from metoclopramide use is likely to be <1%, much less than the estimated 1–10% risk previously suggested in national guidelines. Tardive dyskinesia may represent an idiosyncratic response to metoclopramide; pharmacogenetics affect pharmacokinetic and dopamine receptor pharmacodynamics in response to neuroleptic agents that cause similar neurological complications. Conclusion Community prevalence and pharmacogenetic mechanisms involved in metoclopramide‐induced tardive dyskinesia require further study to define the benefit‐risk ratio more clearly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Its most serious side effect is the occurrence of extrapyramidal movement disorders, tardive dyskinesia, and akathisia in a significant number of patients (30-40%). Drowsiness, fatigue, and depression also occur frequently.”
From Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review (2018) · cites this paper as [56]
Experimental — accuracy not yet measuredIn the citing paper
“The Food and Drug Administration has a black box warning against the chronic use of metoclopramide [56].”
From Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review (2018) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of uses of health care utilization databases for epidemiologic research on therapeutics
Schneeweiß, S., & Avorn, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.012 · Cited by 1,290
Parkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738
Jung, H., Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R., Szarka, L. A., Mullan, B., & Talley, N. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.047 · Cited by 571
A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.
Accili, D., Fishburn, C. S., Drago, J., Steiner, H., Lachowicz, J. E., Park, B.-H., Gauda, E. B., Lee, E.-C., Cool, M. H., Sibley, D. R., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1945 · Cited by 466
Doran, A. C., Obach, R. S., Smith, B. J., Hosea, N. A., Becker, S. L., Callegari, E., Chen, C., Chen, X., Choo, E. F., Cianfrogna, J. A., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001230 · Cited by 443
Abell, T. L., Bernstein, V. K., Cutts, T., Farrugia, G., Forster, J., Hasler, W. L., Mccallum, R. W., Olden, K. W., Parkman, H. P., Parrish, C. R., et al. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00760.x · Cited by 361
Molecular effects of dopamine on striatal-projection pathways
Gerfen, C. R. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00019-7 · Cited by 356
Metoclopramide: Pharmacology and Clinical Application
Albibi, R., & McCallum, R. W. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-86 · Cited by 354
Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology
Reddymasu, S. C., Soykan, I., & McCallum, R. W. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01255.x · Cited by 304
Risk of Tardive Dyskinesia in Older Patients
Jeste, D. V. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950210050010 · Cited by 302
Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G., & de Ponti, F. (2004) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2004.01867.x · Cited by 297
Metoclopramide: Pharmacology and clinical application
Bullard, D. E. (1983) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(83)90196-9 · Cited by 295
Gender Differences in Tardive Dyskinesia: A Critical Review of the Literature
YASSA, R., & Jeste, D. V. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.4.701 · Cited by 267
Ganzini, L. K. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410120051007 · Cited by 266
Lundstrom, K. H., & Turpin, M. P. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1296 · Cited by 232
Extrapyramidal reactions with metoclopramide.
Bateman, D. N., Rawlins, M. D., & Simpson, J. M. (1985) · BMJ · doi:10.1136/bmj.291.6500.930 · Cited by 229
Pasricha, P. J., Pehlivanov, N., Sugumar, A., & Jankovic, J. (2006) · Nature Clinical Practice Gastroenterology &Hepatology · doi:10.1038/ncpgasthep0442 · Cited by 163
Hyett, B., Martinez, F. J., Gill, B. M., Mehra, S., Lembo, A., Kelly, C. P., & Leffler, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.055 · Cited by 158
Shin, J., Soukhova, N. V., & Flockhart, D. A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15029-5 · Cited by 143
Bakker, P. R., van Harten, P. N., & van Os, J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.01.010 · Cited by 141
Desta, Z., Wu, G. M., Morocho, A. M., & Flockhart, D. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.336 · Cited by 113
Lang, I. M., Sarna, S. K., & Condon, R. E. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90072-7 · Cited by 106
Clinical Pharmacokinetics of Metoclopramide
Bateman, D. N. (1983) · Clinical Pharmacokinetics · doi:10.2165/00003088-198308060-00003 · Cited by 105
Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia
Kenney, C., Hunter, C., Davidson, A. L., & Jankovic, J. J. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312258 · Cited by 86
The pharmacokinetics of single doses of metoclopramide in renal failure
Bateman, D. N., Gokal, R., Dodd, T. R. P., & Blain, P. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00548588 · Cited by 84
Diabetes and development of tardive dyskinesia
Woerner, M. G., Saltz, B. L., Kane, J. M., Lieberman, J. A., & Alvir, J. M. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.966 · Cited by 74
Fernández, A. G., & Massingham, R. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90280-2 · Cited by 59
Tardive dyskinesia associated with metoclopramide.
Wiholm, B. ‐., Mortimer, Ö., Boëthius, G., & Häggström, J. E. (1984) · BMJ · doi:10.1136/bmj.288.6416.545 · Cited by 58
Tardive Dyskinesia Risks and Metoclopramide Use Before and After U.S. Market Withdrawal of Cisapride
Shaffer, D., Pamer, C. A., Mackey, A. C., & Butterfield, M. I. (2004) · Journal of the American Pharmacists Association · doi:10.1331/1544345042467191 · Cited by 58
Clinical implications of pharmacogenomics for tardive dyskinesia
Müller, D., Shinkai, T., Luca, V. D., & Kennedy, J. L. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500233 · Cited by 58
Dopamine antagonists in the upper gastrointestinal tract.
Valenzuela, J. E., & Dooley, C. P. (1984) · PubMed · Cited by 53
Jolliet, P., Nion, S., Allain-Veyrac, G., Fénart, L., Hallier-Vanuxeem, D., Bérézowski, V., & Cecchelli, R. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.12.004 · Cited by 50
Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases
Sewell, D. D. (1992) · Archives of Family Medicine · doi:10.1001/archfami.1.2.271 · Cited by 47
Pharmacokinetics of metoclopramide in patients with liver cirrhosis.
Magueur, E., Hagège, H., Attali, P., Singlas, E., Etienne, J. P., & Taburet, A. M. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb05511.x · Cited by 43
Managing Drug-Risk Information — What to Do with All Those New Numbers
Avorn, J., & Schneeweiß, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0905466 · Cited by 41
Metoclopramide and Tardive Dyskinesia
Sewell, D. D., Kodsi, A. B., Caligiuri, M. P., & Jeste, D. V. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90077-9 · Cited by 35
Yoshikawa, T., Yoshida, N., & Oka, M. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704078 · Cited by 20
Effect of metoclopramide, domperidone and apomorphine on GH secretion in children and adolescents
MASSARA, F., Tangolo, D., Godano, A., GOFFI, S., Bertagna, A., & Molinatti, G. M. (1985) · European Journal of Endocrinology · doi:10.1530/acta.0.1080451 · Cited by 8
Cited by
Sorted by citations
Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Gerson, L. B., & Vela, M. F. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.444 · Cited by 1,759
“Th e usage of metoclopramide has been limited by central nervous system side eff ects including drowsiness, agitation, irritability, depression, dystonic reactions, and tardive dyskinesia in 1 % of patients ( 77 ).”
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Dunbar, K. B., Schnoll‐Sussman, F. H., Greer, K. B., Yadlapati, R. H., & Spechler, S. J. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001538 · Cited by 1,064
“However, data on its efficacy in GERD are scant, and significant adverse events have been reported with long-term and high-dosemetoclopramide use, including central nervous system side effects such as drowsiness, agitation, irritability, depression, dystonic reactions, and tardive dyskinesia (72,73).”
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
“Recommendations on when and how to use metoclopramide for the treatment of gastroparesis in clinical practice have been published (93) and include careful monitoring of the patient for earliest signs of tardive dyskinesia (which may be reversible with early recognition and cessation of therapy), use of the lowest effe…”
BackgroundSelf-citationESPEN guidelines on chronic intestinal failure in adults
Pironi, L., Arends, J., Bozzetti, F., Cuerda, C., Gillanders, L. K., Jeppesen, P. B., Joly, F., Kelly, D. G., Lal, S., Staun, M., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.01.020 · Cited by 741
“The use of metoclopramide and domperidone has been limited due to their neurologic and cardiac adverse effects [363].”
BackgroundCamilleri, M., Chedid, V., Ford, A. C., Haruma, K., Horowitz, M., Jones, K. L., Low, P. A., Park, S.-Y., Parkman, H. P., & Stanghellini, V. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0038-z · Cited by 411
Self-citation
Metadata
- Authors
- RAO, A. S., & CAMILLERI, M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- CAMILLERI, M.
- ORCID
- CAMILLERI, M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-12-02
- Volume
- 31
- Issue
- 1
- Pages
- 11-19
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2049233278
- Cited by
- 316
- References
- 38
- Citations by year
- 2026: 15 · 2025: 8 · 2024: 11 · 2023: 16 · 2022: 33 · 2021: 21 · 2020: 24 · 2019: 28 · 2018: 24 · 2017: 21 · 2016: 22 · 2015: 25 · 2014: 18 · 2013: 21 · 2012: 12
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Keywords
- metoclopramide, tardive dyskinesia, dopamine antagonists, pharmacokinetics, pharmacogenetics, cytochrome P450, P-glycoprotein, gastroparesis, black box warning, risk factors, risk-benefit assessment
- MeSH terms
- Dyskinesia, Drug-Induced, Humans, Metoclopramide, Risk Factors, Prevalence, Odds Ratio, Dopamine Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
